Endocrine Abstracts

Introduction: Immune-checkpoint inhibitors (ICIs) have revolutionised cancer treatment, offering superior efficacy compared to traditional chemotherapy. The use of immune checkpoint inhibitors has been associated with the occurrence of multiple endocrine immune-related adverse events (irAEs), such as primary hypothyroidism, thyroiditis, primary adrenal insufficiency, type 1 diabetes mellitus, and hypophysitis. In certain instances, these irAEs may necessitate the discontinuati...